Overview
The Association for Molecular Pathology (AMP) provides structure and leadership to the emerging field of molecular diagnostics. AMP's 2,900+ members include individuals from academic and community medical centers, government, and industry; including pathologist and doctoral scientist laboratory directors; basic and translational scientists; technologists; and trainees.
The AMP Annual Meeting & Expo features more than 200 exhibiting companies, 60 educational sessions, nearly 400 poster presentations, and 3,000+ attendees/exhibitors.
Exhibits will be open from November 21 to November 23. Oxford Nanopore will be located at booth 1510, and will host a Corporate Workshop at 02:00 pm PST on November 20, 2024.
Corporate Workshop
Date: Wednesday, November 20, 2024
Time: 02:00 pm-02:50 pm PST
Location: Room 109, Level 1, Vancouver Convention Center
Join us on Corporate Workshop Day to learn how sequencing solutions from Oxford Nanopore Technologies are transforming molecular pathology. Hear about the latest developments in nanopore sequencing which provide a comprehensive view of both conventionally sequenced single nucleotide variants and small indels, and the detection of structural, repetitive, copy number, and methylation variants ― all in a single sequencing run. With its ability to read any length of DNA or RNA, from short to ultra-long, come and learn how nanopore technology empowers you to answer the bigger and bolder research questions you have always wanted to ask.
If you are not registered to attend the AMP Annual Meeting, you are still welcome to attend Corporate Workshop Day. There is no fee but registration is required. Here is a link to register for the Corporate Workshop Day. https://www.surveymonkey.com/r/AMPCW24
Agenda
02:00 pm-02:50 pm PST | Room 109, Level 1 | |
|---|---|---|
02:00 pm-02:10 pm | Oxford Nanopore introduction and overview | Ellie Juarez, Oxford Nanopore Technologies |
02:10 pm-02:30 pm | Evaluation of a streamlined nanopore sequencing workflow for rare variant characterization in a clinical laboratory setting | Anne-Sophie Lebre, INSERM, REIMS University Hospital, Paris, France |
02:30 pm-02:50 pm | Potential of Nanopore Sequencing for rapid clinical testing in cancer predisposition genes | Stephen Murphy, Director, Genome Analysis Core Mayo Clinic |